Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a heart pill help you walk longer without pain?

NCT ID NCT01037530

Symptom relief Sponsor: Hull University Teaching Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether ramipril, a common blood pressure medicine, can improve walking distance in people with intermittent claudication (leg pain due to narrowed arteries). Researchers planned to enroll 78 adults with stable leg pain, giving half ramipril and half a placebo. They measured maximum walking distance on a treadmill, along with artery function and quality of life. The study is complete, but results are not yet reported.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

33 people

The number who actually took part.

Start date

Dec 2010

Finished

Dec 2012

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with unilateral or bilateral intermittent leg claudication which was stable for the last 6 months. * Patients with ABPI \< 0.9 at rest at least in one leg. * BP ≤ 160/90 and a stable medication regimen for the last 6 months. * Able to give informed consent * Able to comply with study protocol Exclusion Criteria: * Documented bilateral renal artery stenosis * Unlikely to be compliant with medication or follow up as determined by the recruiting institution. * Pregnancy * Patients with critical limb ischemia (This includes patients with ischaemic rest pain and ulceration \> 2 weeks and/or a resting ankle pressure \< 50mmHg- Grades II and III according to Rutherford et al 1997.\[56\]. * Patients who had a recent (less than 3 months) angioplasty or bypass surgery * Patients who are unable to perform a treadmill test due to a limiting heart, respiratory or arthritic disease * History of angioneurotic oedema * Currently taking ACE inhibitor or Angiotensin receptor blocker * Contraindication to ACE inhibitor * History of ACE inhibitor intolerance * A creatinine rise of \> 30% from baseline and/or Potassium \> 5.9 mmol/l * Unwillingness to participate. * Level 1 evidence for ACE inhibitor treatment, including: * Documented heart failure, left ventricular dysfunction or ejection fraction \<35% on previous echocardiography * Uncontrolled hypertension, BP \> 160mmHg systolic or 100mmHg diastolic on 3 separate readings measured after 10 minutes rest on 2 separate occasions * Recent (\< 3months) myocardial infarction or stroke * Chronic renal impairment (serum creatinine \> 250 micromol/l)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intermittent claudicants are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intermittent vascular claudication

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intermittent claudicants

Contacts and locations

Locations

  • Hull and East Yorkshire Hospitals

    Hull, Yorkshire, HU3 2JZ, United Kingdom